A Phase 3 interventional study of Dupilumab SAR231893 and Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease, sponsored by Sanofi. Completed at 275 sites in 24 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-28.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi — 7 open to participants now, 7 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sanofi.
Among the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2019, is one of 8 in phase 3, and was the 2nd registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →7 of the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States
Ages 40+
Sanofi · Sites in France
Ages 18+
Sanofi · Sites in United States, Argentina, Austria and 19 more countries
Ages 40–85
Sanofi · Sites in United States, Argentina, Australia and 23 more countries
Ages 40–80
Sanofi · Sites in United States, Argentina, Belgium and 22 more countries
Ages 40–80
By country, each count listing its studies:
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2019.
This study's enrollment of 939 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 937 across the 12 interventional studies, 350 across the 3 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate-or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by
Secondary Objectives:
To evaluate the effect of dupilumab administered every 2 weeks on
Approximately 68 weeks including a 4-week screening period, a 52-week treatment period, and 12 weeks of follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with a physician diagnosis of who met the following criteria at screening:
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received dupilumab 300 mg administered as SC injections q2w up to a maximum of 52 weeks (last dose administered at Week 50, EOT visit occurred 2 weeks after last administration of treatment i.e., at Week 52).
Drug: Dupilumab SAR231893 · Drug: Inhaled Corticosteroid · Drug: Inhaled Long-Acting Beta Agonist · Drug: Inhaled Long-Acting Muscarinic Antagonist
Participants received placebo matched to dupilumab 300 mg as subcutaneous (SC) injections q2w up to a maximum of 52 weeks (last dose administered at Week 50, end of treatment \[EOT\] visit occurred 2 weeks after last administration of treatment i.e., at Week 52).
Drug: Inhaled Corticosteroid · Drug: Inhaled Long-Acting Beta Agonist · Drug: Inhaled Long-Acting Muscarinic Antagonist · Drug: Placebo
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Also known as: Dupixent
Pharmaceutical form: Inhaled Powder Route of administration: Oral inhalation
Pharmaceutical form: Inhaled Powder Route of administration: Oral inhalation
Pharmaceutical form: Inhaled Powder Route of administration: Oral inhalation
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment Period
Moderate exacerbations were recorded by the Investigator and defined as acute exacerbation of COPD (AECOPD) that required either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations were also recorded by the Investigator and defined as AECOPD requiring hospitalization, or observation for \>24 hours in an emergency department/urgent care facility or resulting in death. For both moderate and severe events to be counted as separate events, they were separated by at least 14 days. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated. Events were adjudicated by independent third party.
Time frame: Baseline (Day 1) to Week 52
Change From Baseline in Pre-Bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1) at Week 12
The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration.
Time frame: Baseline (Day 1) to Week 12
Change From Baseline in Pre-BD FEV1 at Week 52
The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration.
Time frame: Baseline (Day 1) to Week 52
Change From Baseline in Pre-BD FEV1 at Week 12 in Subgroup of Participants With Baseline Fractional Exhaled Nitric Oxide (FeNO) >=20 Parts Per Billion (Ppb)
FeNO is a demonstrated biomarker of type 2 airway inflammation in respiratory diseases. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 milliliter per second (mL/s) and reported in ppb. This assessment was conducted prior to spirometry and following a fast of at least 1 hour.
Time frame: Baseline (Day 1) to Week 12
Change From Baseline in Pre-BD FEV1 at Week 52 in Subgroup of Participants With Baseline FeNO >=20 Ppb
FeNO is a demonstrated biomarker of type 2 airway inflammation in respiratory diseases. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/s and reported in ppb. This assessment was conducted prior to spirometry and following a fast of at least 1 hour.
Time frame: Baseline (Day 1) to Week 52
Change From Baseline in Saint (St.) George's Respiratory Questionnaire (SGRQ) Total Score at Week 52
The SGRQ was a 50-item self-administered questionnaire designed to measure and quantify health status in adult participants with chronic airflow limitation and rated on electronic diary. Scores by dimension were calculated for 3 domains: symptoms, activity and impacts (psycho-social) as well as a total score. Global and domain scores range from 0 to 100, with 100 representing the worst possible health status and 0 indicating the best possible health status. Higher score indicates worse health status/heath related quality of life.
Time frame: Baseline (Day 1) to Week 52
Percentage of Participants With SGRQ Improvement >=4 Points at Week 52
A responder was defined as a participant with improvement from baseline in SGRQ total score at Week 52 by \>=4 points. Participants with improvement \<4 points or with missing values were considered as non-responders. The percentage of participants who achieved a clinically meaningful response in SGRQ total score (reduction \[improvement\] by \>=4 points)/responders are reported.
Time frame: Baseline (Day 1) to Week 52
Change From Baseline in Evaluating Respiratory Symptoms (E-RS) in COPD (E-RS: COPD) RS-Total Score at Week 52
The E-RS in COPD scale was a part of the exacerbations of chronic pulmonary disease tool (EXACT). It was a derivative instrument used to measure the effect of treatment on the severity of respiratory symptoms in stable COPD. E-RS: COPD RS-Total Score was derived based on weekly averages of daily assessed 11 respiratory symptom items contained in the 14-item EXACT questionnaire. The RS-Total score represented overall respiratory symptom severity, ranged from 0 to 40. Summation procedure was used to derive the three daily domain scores: 1). RS-Breathlessness (range 0-17), 2) RS-Cough and Sputum (score range 0-11), 3) RS-Chest Symptoms (score range 0-12). The higher the score, more severe were the symptoms.
Time frame: Baseline (Day 1) to Week 52
Annualized Rate of Moderate or Severe COPD Exacerbation Over the 52-Week Treatment Period in Subgroup of Participants With Baseline FeNO >=20 Ppb
Moderate exacerbations were recorded by the Investigator and defined as AECOPD that required either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations were also recorded by the investigator and defined as AECOPD requiring hospitalization, or observation for \>24 hours in an emergency department/urgent care facility or resulting in death. For both moderate and severe events to be counted as separate events, they were separated by at least 14 days. Annualized event rate among participants with baseline FeNO \>=20 ppb was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated. Events were adjudicated by independent third party.
Time frame: Baseline (Day 1) to Week 52
Change From Baseline in Pre-BD FEV1 to Weeks 2, 4, 8, 24, 36 and 44
The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration.
Time frame: Baseline (Day 1) to Weeks 2, 4, 8, 24, 36 and 44
Change From Baseline in Post-BD FEV1 to Weeks 2, 4, 8, 12, 24, 36 and 52
The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Post-BD FEV1 referred to the spirometry performed within 30 minutes after administration of bronchodilator.
Time frame: Baseline (Day 1) to Weeks 2, 4, 8, 12, 24, 36 and 52
Change From Baseline in Pre-BD Forced Expiratory Flow at 25 Percent (%) to 75% (FEF 25-75%) of Forced Vital Capacity (FVC) to Weeks 2, 4, 8, 12, 24, 36, 44, and 52
FEF is the amount of air (in liters) which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Spirometry was performed after a wash out period of bronchodilators according to their action duration.
Time frame: Baseline (Day 1) to Weeks 2, 4, 8, 12, 24, 36, 44 and 52
Change From Baseline in Post-BD FEF 25-75% to Weeks 2, 4, 8, 12, 24, 36 and 52
FEF is the amount of air (in liters) which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Spirometry was performed after a wash out period of bronchodilators according to their action duration.
Time frame: Baseline (Day 1) to Weeks 2, 4, 8, 12, 24, 36 and 52
Annualized Rate of Severe COPD Exacerbations Over the 52-Week Treatment Period
Moderate exacerbations were recorded by the Investigator and defined as AECOPD that required either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations were also recorded by the Investigator and defined as AECOPD requiring hospitalization, or observation for \>24 hours in an emergency department/urgent care facility or resulting in death. For both moderate and severe events to be counted as separate events, they were separated by at least 14 days. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated. Events were adjudicated by independent third party.
Time frame: Baseline (Day 1) to Week 52
Time to First Moderate or Severe COPD Exacerbation During the 52-Week Treatment Period
The time to first moderate or severe exacerbation was defined as date of the first event minus randomization date +1. The median time to first severe exacerbation was derived from Cox regression model. Moderate exacerbations events were recorded by the investigator and defined as AECOPD that require either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations were recorded by the Investigator and defined as AECOPD requiring hospitalization, or observation for \>24 hours in an emergency department/urgent care facility or resulting in death. For both moderate and severe events to be counted as separate events, they were separated by at least 14 days.
Time frame: Baseline (Day 1) and up to Weeks 12, 24, 36 and 52
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
An Adverse Event (AE) was defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were defined as AEs that developed or worsened in grade or became serious during TE period which was defined as the period from the time of first dose of study treatment until the last visit in the study. Serious adverse events (SAE) were defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.
Time frame: TEAEs were collected from the time from the first administration of study treatment to the last administration of the study treatment + 98 days, up to 491 days
Number of Participants With Anti-Drug Antibodies (ADA) to Dupilumab
Number of participants with treatment-emergent response to dupilumab with peak post-baseline titers during the on-treatment period are reported. Treatment-emergent response was defined as a positive response in the ADA assay post first dose, when baseline results were negative or missing. Categories were based on titer values and included: low (Titer \<1000); moderate (1000\<=Titer\<=10,000); and high (Titer \>10,000). On-treatment period was defined as last study treatment administration plus 14 days; that is, Week 52.
Time frame: Up to Week 52
The study was conducted at 275 centers in 24 countries. A total of 2599 participants were screened from 15 Apr 2019 to 12 Jan 2022, of which 1660 were screen failures due to not meeting eligibility criteria.
| Milestone | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Started | 471 | 468 |
| Safety population | 470 | 469 |
| Completed | 434 | 440 |
| Not completed | 37 | 28 |
| Withdrew: Adverse event | 9 | 7 |
| Withdrew: Poor compliance to protocol | 0 | 1 |
| Withdrew: Withdrawal by subject | 23 | 11 |
| Withdrew: Other reason related to coronavirus disease-2019 (covid-19) | 0 | 1 |
| Withdrew: Other reason not related to covid-19 | 5 | 8 |
Moderate exacerbations were recorded by the Investigator and defined as acute exacerbation of COPD (AECOPD) that required either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations were also recorded by the Investigator and defined as AECOPD requiring hospitalization, or observation for \>24 hours in an emergency department/urgent care facility or resulting in death. For both moderate and severe events to be counted as separate events, they were separated by at least 14 days. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated. Events were adjudicated by independent third party.
| exacerbation per participant-year | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment Period | 1.01 (0.931 to 1.301) | 0.776 (0.645 to 0.934) |
The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration.
| liters | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Change From Baseline in Pre-Bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1) at Week 12 | 0.077 ± 0.018 | 0.160 ± 0.018 |
The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration.
| liters | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Change From Baseline in Pre-BD FEV1 at Week 52 | 0.070 ± 0.019 | 0.153 ± 0.019 |
FeNO is a demonstrated biomarker of type 2 airway inflammation in respiratory diseases. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 milliliter per second (mL/s) and reported in ppb. This assessment was conducted prior to spirometry and following a fast of at least 1 hour.
| liters | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Change From Baseline in Pre-BD FEV1 at Week 12 in Subgroup of Participants With Baseline Fractional Exhaled Nitric Oxide (FeNO) >=20 Parts Per Billion (Ppb) | 0.108 ± 0.035 | 0.232 ± 0.034 |
FeNO is a demonstrated biomarker of type 2 airway inflammation in respiratory diseases. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/s and reported in ppb. This assessment was conducted prior to spirometry and following a fast of at least 1 hour.
| liters | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Change From Baseline in Pre-BD FEV1 at Week 52 in Subgroup of Participants With Baseline FeNO >=20 Ppb | 0.120 ± 0.037 | 0.247 ± 0.036 |
The SGRQ was a 50-item self-administered questionnaire designed to measure and quantify health status in adult participants with chronic airflow limitation and rated on electronic diary. Scores by dimension were calculated for 3 domains: symptoms, activity and impacts (psycho-social) as well as a total score. Global and domain scores range from 0 to 100, with 100 representing the worst possible health status and 0 indicating the best possible health status. Higher score indicates worse health status/heath related quality of life.
| score on a scale | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Change From Baseline in Saint (St.) George's Respiratory Questionnaire (SGRQ) Total Score at Week 52 | -6.369 ± 0.816 | -9.732 ± 0.810 |
A responder was defined as a participant with improvement from baseline in SGRQ total score at Week 52 by \>=4 points. Participants with improvement \<4 points or with missing values were considered as non-responders. The percentage of participants who achieved a clinically meaningful response in SGRQ total score (reduction \[improvement\] by \>=4 points)/responders are reported.
| percentage of participants | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Percentage of Participants With SGRQ Improvement >=4 Points at Week 52 | 43.1 | 51.5 |
The E-RS in COPD scale was a part of the exacerbations of chronic pulmonary disease tool (EXACT). It was a derivative instrument used to measure the effect of treatment on the severity of respiratory symptoms in stable COPD. E-RS: COPD RS-Total Score was derived based on weekly averages of daily assessed 11 respiratory symptom items contained in the 14-item EXACT questionnaire. The RS-Total score represented overall respiratory symptom severity, ranged from 0 to 40. Summation procedure was used to derive the three daily domain scores: 1). RS-Breathlessness (range 0-17), 2) RS-Cough and Sputum (score range 0-11), 3) RS-Chest Symptoms (score range 0-12). The higher the score, more severe were the symptoms.
| score on a scale | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Change From Baseline in Evaluating Respiratory Symptoms (E-RS) in COPD (E-RS: COPD) RS-Total Score at Week 52 | -1.558 ± 0.256 | -2.694 ± 0.257 |
Moderate exacerbations were recorded by the Investigator and defined as AECOPD that required either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations were also recorded by the investigator and defined as AECOPD requiring hospitalization, or observation for \>24 hours in an emergency department/urgent care facility or resulting in death. For both moderate and severe events to be counted as separate events, they were separated by at least 14 days. Annualized event rate among participants with baseline FeNO \>=20 ppb was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated. Events were adjudicated by independent third party.
| exacerbation per participant-year | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Annualized Rate of Moderate or Severe COPD Exacerbation Over the 52-Week Treatment Period in Subgroup of Participants With Baseline FeNO >=20 Ppb | 1.117 (0.831 to 1.502) | 0.699 (0.510 to 0.958) |
The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration.
| liters | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Week 2 | 0.075 ± 0.017 | 0.159 ± 0.017 |
| Week 4 | 0.069 ± 0.017 | 0.163 ± 0.017 |
| Week 8 | 0.069 ± 0.017 | 0.149 ± 0.017 |
| Week 24 | 0.068 ± 0.018 | 0.170 ± 0.018 |
| Week 36 | 0.072 ± 0.018 | 0.155 ± 0.018 |
| Week 44 | 0.089 ± 0.019 | 0.176 ± 0.019 |
The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Post-BD FEV1 referred to the spirometry performed within 30 minutes after administration of bronchodilator.
| liters | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Week 2 | 0.071 ± 0.017 | 0.158 ± 0.017 |
| Week 4 | 0.080 ± 0.017 | 0.158 ± 0.017 |
| Week 8 | 0.077 ± 0.018 | 0.153 ± 0.018 |
| Week 12 | 0.084 ± 0.018 | 0.156 ± 0.018 |
| Week 24 | 0.072 ± 0.019 | 0.169 ± 0.019 |
| Week 36 | 0.072 ± 0.019 | 0.155 ± 0.019 |
| Week 52 | 0.058 ± 0.019 | 0.138 ± 0.019 |
FEF is the amount of air (in liters) which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Spirometry was performed after a wash out period of bronchodilators according to their action duration.
| liters/second | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Week 2 | 0.065 ± 0.016 | 0.110 ± 0.016 |
| Week 4 | 0.066 ± 0.015 | 0.115 ± 0.015 |
| Week 8 | 0.069 ± 0.016 | 0.114 ± 0.016 |
| Week 12 | 0.076 ± 0.016 | 0.137 ± 0.016 |
| Week 24 | 0.080 ± 0.017 | 0.142 ± 0.017 |
| Week 36 | 0.087 ± 0.017 | 0.132 ± 0.017 |
| Week 44 | 0.091 ± 0.017 | 0.162 ± 0.017 |
| Week 52 | 0.088 ± 0.017 | 0.135 ± 0.017 |
FEF is the amount of air (in liters) which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Spirometry was performed after a wash out period of bronchodilators according to their action duration.
| liters/second | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Week 2 | 0.074 ± 0.017 | 0.135 ± 0.017 |
| Week 4 | 0.087 ± 0.017 | 0.144 ± 0.017 |
| Week 8 | 0.083 ± 0.017 | 0.144 ± 0.017 |
| Week 12 | 0.089 ± 0.018 | 0.161 ± 0.018 |
| Week 24 | 0.093 ± 0.019 | 0.169 ± 0.019 |
| Week 36 | 0.093 ± 0.019 | 0.161 ± 0.018 |
| Week 52 | 0.093 ± 0.019 | 0.153 ± 0.019 |
Moderate exacerbations were recorded by the Investigator and defined as AECOPD that required either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations were also recorded by the Investigator and defined as AECOPD requiring hospitalization, or observation for \>24 hours in an emergency department/urgent care facility or resulting in death. For both moderate and severe events to be counted as separate events, they were separated by at least 14 days. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated. Events were adjudicated by independent third party.
| exacerbation per participant-year | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Annualized Rate of Severe COPD Exacerbations Over the 52-Week Treatment Period | 0.086 (0.050 to 0.147) | 0.072 (0.040 to 0.132) |
The time to first moderate or severe exacerbation was defined as date of the first event minus randomization date +1. The median time to first severe exacerbation was derived from Cox regression model. Moderate exacerbations events were recorded by the investigator and defined as AECOPD that require either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations were recorded by the Investigator and defined as AECOPD requiring hospitalization, or observation for \>24 hours in an emergency department/urgent care facility or resulting in death. For both moderate and severe events to be counted as separate events, they were separated by at least 14 days.
| weeks | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Up to Week 12 | 0.019 (0.009 to 0.035) | 0.024 (0.013 to 0.041) |
| Up to Week 24 | 0.039 (0.024 to 0.059) | 0.034 (0.021 to 0.054) |
| Up to Week 36 | 0.045 (0.029 to 0.067) | 0.039 (0.024 to 0.059) |
| Up to Week 52 | 0.061 (0.042 to 0.086) | 0.043 (0.027 to 0.065) |
An Adverse Event (AE) was defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were defined as AEs that developed or worsened in grade or became serious during TE period which was defined as the period from the time of first dose of study treatment until the last visit in the study. Serious adverse events (SAE) were defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.
| Participants | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Any TEAE | 359 | 365 |
| Any TESAE | 74 | 65 |
Number of participants with treatment-emergent response to dupilumab with peak post-baseline titers during the on-treatment period are reported. Treatment-emergent response was defined as a positive response in the ADA assay post first dose, when baseline results were negative or missing. Categories were based on titer values and included: low (Titer \<1000); moderate (1000\<=Titer\<=10,000); and high (Titer \>10,000). On-treatment period was defined as last study treatment administration plus 14 days; that is, Week 52.
| Participants | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Low titer | 7 | 27 |
| Moderate titer | 0 | 1 |
| High titer | 0 | 2 |
Collected over TEAEs were collected from the time from the first administration of study treatment to the last administration of the study treatment + 98 days, up to 491 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 9/470 (1.9%) | 74/470 (15.7%) | 172/470 (36.6%) |
| Dupilumab 300 mg q2w | 8/469 (1.7%) | 65/469 (13.9%) | 168/469 (35.8%) |
| Event | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 26/470 | 28/469 |
| PneumoniaInfections and infestations | 12/470 | 6/469 |
| Covid-19 PneumoniaInfections and infestations | 5/470 | 2/469 |
| Covid-19Infections and infestations | 4/470 | 3/469 |
| Lower Respiratory Tract InfectionInfections and infestations | 2/470 | 3/469 |
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 3/470 | 1/469 |
| Cerebral HaemorrhageNervous system disorders | 0/470 | 2/469 |
| Cardiac FailureCardiac disorders | 2/470 | 2/469 |
| Coronary Artery DiseaseCardiac disorders | 1/470 | 2/469 |
| Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders | 2/470 | 2/469 |
| Event | Placebo | Dupilumab 300 mg q2w |
|---|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 46/470 | 37/469 |
| NasopharyngitisInfections and infestations | 45/470 | 45/469 |
| HeadacheNervous system disorders | 33/470 | 38/469 |
| Accidental OverdoseInjury, poisoning and procedural complications | 30/470 | 26/469 |
| HypertensionVascular disorders | 28/470 | 17/469 |
| DiarrhoeaGastrointestinal disorders | 17/470 | 25/469 |
| Back PainMusculoskeletal and connective tissue disorders | 16/470 | 25/469 |
The Randomized population consisted of any participant who was allocated to a randomized treatment regardless of whether the treatment kit was used.
| Age, Continuous(years) | Placebo | Dupilumab 300 mg q2w | Total |
|---|---|---|---|
| Median | 65.2 ± 8.1 | 65.0 ± 8.0 | 65.1 ± 8.1 |
| Sex: Female, Male(Participants) | Placebo | Dupilumab 300 mg q2w | Total |
|---|---|---|---|
| Female | 149 | 170 | 319 |
| Male | 322 | 298 | 620 |
| Race (NIH/OMB)(Participants) | Placebo | Dupilumab 300 mg q2w | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 3 | 7 |
| Asian | 67 | 67 | 134 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 2 | 3 | 5 |
| White | 397 | 393 | 790 |
| More than one race | 0 | 2 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
Showing the first 100 of 275 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Apr 2019 to primary completion in Feb 2023, 45 months.
Results were first posted in Feb 2024, 1 year after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 45 months is above that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab
Pulmonary Disease, Chronic Obstructive →